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Advances in treating bronchopulmonary dysplasia 
 
SUMMARY  
Introduction:  Bronchopulmonary dysplasia (BPD) is a common long-term adverse 
complication of very premature delivery.  Affected infants can suffer chronic 
respiratory morbidity including lung function abnormalities and reduced exercise 
capacity even as young adults. Many studies have investigated possible preventative 
strategies, but it is equally important to identify optimum management strategies for 
infants with evolving or established BPD and the focus of this review. 
Areas covered:  Respiratory support modalities and established and novel 
pharmacological treatments. 
Expert commentary: Respiratory support modalities including proportional assist 
ventilation and neurally adjusted ventilatory assist are associated with short term 
improvements in oxygenation indices.  Such modalities now need to be investigated 
in appropriate RCTs. Many pharmacological treatments are routinely used with a 
limited evidence base, for example diuretics.  Stem cell therapies in small case series 
are associated with promising results, but more research is required before it is 
possible to determine if such therapies should be investigated in large RCTs with 
long-term outcomes.   
Keywords  
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Prematurity  
Pulmonary  
Mesenchymal stem cells  
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INTRODUCTION 
 
Bronchopulmonary dysplasia (BPD) is the most common long-term adverse outcome 
of very premature delivery. BPD is currently defined as a requirement for treatment 
with supplemental oxygen for more than twenty-eight days and then categorised at 36 
weeks post-menstrual age for severity according to the level of respiratory support 
required [1].   The so-called ‘new BPD’ is characterised by impairment of 
alveolarisation and vascularisation of pulmonary vessels [1]. Unfortunately, it is 
associated with chronic respiratory morbidity [2, 3]. This includes chronic oxygen 
dependency which, in the most severely affected cases results in a supplementary 
oxygen requirement at home [3].  In addition, children who have had BPD can have 
troublesome respiratory symptoms requiring treatment and lung function 
abnormalities at follow up.  These problems may persist at least into young adulthood 
[4].  It is, therefore, essential infants with BPD are appropriately treated to reduce 
long term adverse outcomes.  It has, however, been demonstrated amongst infants 
with severe BPD cared for in eight neonatal intensive care units in the USA, there was 
variation between centres in the use of mechanical ventilation at 28 days and 36 
weeks post-menstrual age (PMA) and the use of diuretics, inhaled corticosteroids and 
inhaled β-antagonists. The authors concluded that the variation likely reflected the 
lack of evidence in guiding optimal management of such infants [5]. Our aim, 
therefore, was to review the literature to identify evidence-based management 
strategies and promising treatments for infants with BPD.  
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1. Respiratory support modalities 
Many infants with evolving or established BPD require mechanical ventilation.  
Indeed, we have shown that infants who were ventilator dependent at seven days were 
extremely likely to develop BPD (99% sensitivity) [6]. There is, however, limited 
evidence to determine which ventilator mode should be used in infants with evolving 
or established BPD. 
 
1.1 Volume targeted ventilation (VTV) 
VTV has been demonstrated in a systematic review of eighteen trials to be associated 
with a lower incidence of BPD at 36 weeks post menstrual age when compared with 
pressure limited ventilation strategies [7].  In a study of eighteen infants with evolving 
or established BPD the work of breathing (WOB), determined by measurement of the 
pressure time product of the diaphragm, was assessed at different levels of targeted 
volume ventilation.  Only at a target tidal volume of 7 mls/kg was the WOB reduced 
significantly below baseline [8], that result likely reflects the increased physiological 
dead space in infants with BPD [9].  Whether use of such a target tidal volume in 
infants with BPD improves their long-term outcome needs investigating. 
 
1.2 Proportional assist ventilation (PAV)  
 
During PAV, the applied pressure is servo controlled throughout each spontaneous 
breath.  The applied pressures increase in proportion to the tidal volume (elastic 
unloading) or flow (resistive unloading) generated by the patient.  The frequency, 
timing and magnitude of lung inflation are controlled by the patient [10].  In a 
randomised, crossover study of four-hour epochs, PAV compared to patient triggered 
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ventilation (PTV) was associated with significantly lower mean airway pressure 
(MAP) and peak inflation pressure (PIP), but similar blood gases.  The duration of 
desaturations, however, was significantly longer during PAV [11].  Since then, the 
back-up facility has been enhanced.  Two recent studies in infants with evolving or 
established BPD have shown PAV was associated with a reduction in the oxygenation 
index compared to assist control ventilation (ACV) when each were studied in one 
hour epochs [12] and similarly when each were studied for four hour epochs [13].  In 
addition, the WOB was lower after one hour of PAV compared to one hour of ACV 
[12].    
 
1.3 Neurally adjusted ventilatory assist (NAVA)  
During NAVA, the diaphragmatic electrical (Edi) activity triggers ventilator inflations 
[14] and also unloads the infant’s respiratory abnormalities by delivering pressure 
proportional to the Edi signal. The clinician can set the NAVA level (or gain factor) 
to increase or decrease the level of respiratory support delivered by the ventilator.  In 
one study of 29 preterm infants, 21 of whom had severe BPD and were mechanically 
ventilated at greater than four weeks post menstrual age, there was a significant 
improvement in oxygen saturation levels and reduced PaCO2 levels when the infants 
were transitioned to NAVA [15]. The WOB was measured in only nine of the infants, 
but in all it was significantly lower on NAVA [15].  In a randomised crossover study 
of preterm infants with evolving or established BPD, nine infants were randomised to 
receive assist control ventilation (ACV) or NAVA for one hour and then switched to 
the other mode of ventilation for a subsequent hour. On NAVA, the oxygenation 
index was significantly lower [16]. A retrospective study of 14 preterm infants who 
underwent tracheostomy and mechanical ventilation for more than six months 
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demonstrated that the nine who had been supported by NAVA for at least two months 
had less cyanotic episodes and received less sedation and dexamethasone [17].  Both 
PAV and NAVA give the ability to unload the infant’s lung function abnormalities, 
hence the explanation for the improvements in oxygenation indices in short-term 
studies compared to traditional triggered modes.  The two modes now need to be 
compared to determine which mode should be investigated further in a large RCT 
investigating long-term efficacy in infants with BPD.  
 
1.4 Home ventilation 
Infants with severe BPD when ventilated at home require to be able to trigger a 
portable ventilator [18]. Portable ventilators such as the LTV 1200 (CareFusion, 
Yorba Linda, CA) and Trilogy 202 (Philips Healthcare, Andover, MA) have less rapid 
response times with an increase in dead space compared to intensive care ventilators 
[18]. Infants with poor trigger response on portable ventilators can experience 
ventilator asynchrony requiring sedation and an increase in ventilatory settings [18]. It 
is, therefore, crucial in order to be able to transition these infants early to portable 
home ventilators that the most appropriate ventilator is used. A pilot study of six 
infants with severe BPD who were mechanically ventilated via tracheostomy 
demonstrated with each infant acting as their own control, there was a statistically 
significant higher number of spontaneously triggered breaths with the Trilogy 202 
ventilator compared to the LTV 1200 and infants had a lower work of breathing and 
better synchrony [18]. Clearly, larger studies are required to identify the optimum 
ventilator type and more studies developing devices to optimise home ventilators are 
required.    
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1.5 Non-invasive ventilation 
Volutrauma is an important risk factor for lung injury, thus in infants with BPD it is 
important to extubate them as soon as possible.  Unfortunately, there are few studies 
to determine which is the most appropriate non-invasive mode to support such infants. 
In a crossover study of twenty infants with evolving or established BPD, and a 
median postnatal age of 30.9 weeks, the WOB did not differ significantly when the 
infants were supported by positive airway pressure (CPAP) or heated humidified, 
high-flow nasal cannulae (HHFNC).  There were also no significant differences in the 
oxygen saturation levels of infants between the two modes [19].  The infants included 
in the study had relatively mild chronic respiratory distress and it would be important 
to assess if such results are generalisable to all BPD infants and confirmed in 
randomised trials.  
 
1.6 Heliox 
Heliox is a helium-oxygen mixture (80:20 ratio) and due to its reduced density may 
improve gas flow in the airways by reducing turbulence and increasing oxygen and 
carbon dioxide diffusion in the alveoli. In a pilot study of 15 infants with severe BPD 
who were ventilation dependent, heliox during mechanical ventilation was associated 
with a reduction in the oxygenation index and improvement in compliance and peak 
expiratory flow rate.  The study, however, was very short-term, comparison of two 
epochs of sixty minutes.  Longer term studies are required to appropriately assess the 
efficacy of this treatment [20]. 
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2.   Pharmacological 
2.1  Corticosteroids 
2.1.1 Systemic corticosteroids 
 
A systematic review of  nineteen randomised controlled trials which in total included 
1345  preterm infants who were either oxygen or ventilator dependent at greater than 
three weeks of postnatal age demonstrated corticosteroid treatment aided extubation 
success and reduced chronic lung disease at 36 weeks PMA aiding discharge to home 
oxygen therapy [21]. Systemic administration of corticosteroids, however, has been 
demonstrated to have long-term adverse effects. A retrospective study which included 
preterm infants who were either ventilator dependent or requiring continuous positive 
airway pressure support with an oxygen requirement of greater than 30% at beyond 
twenty-one days after birth [22] demonstrated infants who received dexamethasone 
had worse neurodevelopmental impairment at 18-22 months of corrected age [22]. 
Within the corticosteroid group, a cumulative dose greater than 5mg/kg was shown to 
be significantly associated with adverse neurodevelopmental outcomes [22].  
Respiratory function at 11 to 14 years has been shown to be significantly impaired in 
those who received postnatal dexamethasone either as prevention or treatment for 
BPD [23]. It has also been reported that 18 year olds who were born extremely 
prematurely and received a cumulative mean dose of 7.7 mg/kg had smaller total 
brain volumes and smaller white matter, thalami and basal ganglia volumes on T1-
weighted magnetic resonance imaging.  There was a trend of small total brain and 
white matter volumes with increasing doses of postnatal dexamethasone [24]. 
 
A moderate (< 4 mg/kg cumulative dose) versus a high (> 4mg/kg cumulative dose) 
was associated with an increased risk of BPD (RR 1.5 (1.01-2.22)) and increased 
Expert review in respiratory medicine  
10 
 
abnormal neurodevelopment (RR 8.33 (1.63-42.48)), but early versus moderately 
early or delayed administration was not associated with an increased risk in the 
primary outcome.  A pulse (three days of 0.5 mg/kg/day) versus a continuous course 
was associated with an increased risk of death or BPD [25]. 
 
 
2.1.2 Inhaled corticosteroids 
In a review of 1429 infants with evolving BPD at 28 days, born less than 29 weeks of 
gestation in 335 USA units, 25% (0-60%) received inhaled steroids (betamethasone, 
budesonide or fluticasone) from three weeks of age, use peaking on day 67.  Use was 
most common in those born below 24 weeks of gestational age and who required 
prolonged ventilation [26].   The evidence to support such usage is, however, limited. 
Late inhalation of inhaled steroids (> 7 days) had been assessed in eight trials, but 
only including in total randomisation of 232 infants.  There were no significant 
differences in BPD or death or in the durations of mechanical ventilation of oxygen 
dependency.  There was, however, a reduced risk of failure to extubate (RR 0.80, 95% 
CI 0.66-0.98) [27].  Long-term outcomes have rarely been reported, but short-term 
efficacy appears dose related [28].  Hydrofluoroalkane-beclomethasone diproprionate 
is a new inhaled corticosteroid with a unique small size (1.1μm) compared to 3.4 to 4 
μm of chlorofluorocarbon-beclomethaonse diproprionate, 2 to 3.2 μm of fluticasone 
and 3.5 μm of budesonide.  This means there is greater lung deposition thus a small 
dose can be used.  In a double-blind, randomised placebo- controlled pilot study 
assessing the efficacy of hydrofluoroalkane beclomethasone dipropronate in infants 
with moderate to severe BPD, no significant differences were seen between the two 
groups with regard to length of stay, rehospitalisations or requirement for additional 
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steroids.  The authors, however, admit the study was underpowered as only 38 infants 
were included [29]. 
 
2.1.3 Inhaled versus systemic corticosteroids    
Randomised or quasi-randomised trials have compared inhaled versus systemic 
steroids in infants ventilator dependent after the first weeks after birth, such infants 
are extremely likely to develop BPD [6].  Systematic review of three trials which 
included in total 431 infants randomised at 12 days or later demonstrated that there 
was no significant difference in the incidence of death or BPD at 36 weeks PMA, the 
relative risk was 1.04 (95% CI (0.86-1.26)). Equally, there was no evidence of 
difference in adverse events profile [30]. 
 
2.1.4 Inhaled bronchodilators  
A retrospective review of 1429 infants born at less than 29 weeks of gestational age 
demonstrated 33% had received bronchodilators.  The length of mechanical 
ventilation (>54 days OR 19.6) best predicted bronchodilator use.  The frequency and 
duration, however, were very variable between centres [31].  That variability likely 
reflects the lack of evidence to support bronchodilator use.  Studies in ventilated 
infants have shown only short-term benefits in ventilated infants.  At follow up, 
however, RCTs in wheezy prematurely born infants have highlighted reduced 
symptoms [32, 33].  
  
2.2 Leukotriene receptor blockade 
Montelukast is a selective leukotriene receptor antagonist of cysteinyl leukotriene 
[34]. Cysteinyl leukotriene causes bronchoconstriction, mucus secretion, airway 
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hyperactivity and increased vascular permeability [35]. The effect of daily 
montelukast therapy (1 mg/kg increasing to 1.5 mg/kg and finally 2 mg/kg) for at 
least three weeks administered to 11 preterm infants who required mechanical 
ventilatory support at twenty-eight days after birth was compared to eleven controls 
[36].  Seven controls died due to respiratory failure, whereas the one non-survivor in 
the montelukast group died post operatively from sepsis following necrotizing 
enterocolitis. There was also a significant decrease in the pulmonary severity score or 
the duration of ventilation between the groups [36]. No adverse effects related to 
montelukast therapy were reported.  The study, however, was not randomised nor 
blinded, but the controls were matched for gestational age, birth weight and 
pulmonary severity score [36]. A subsequent study which was a prospective, 
multicentre, randomised controlled trial of 66 infants born at less than 32 weeks of 
gestational age with a postnatal age greater than 14 days, all ventilator or 
supplementary oxygen dependent demonstrated no significant difference in the 
incidence of moderate to severe BPD (43.4% versus 52.8%, p=0.912) [37]. The long-
term efficacy of montelukast needs to be determined in an appropriately randomised 
trial. 
 
3. Pulmonary vasodilators 
 
Infants with severe BPD can experience both systemic and pulmonary hypertension 
which contributes to their respiratory and cardiovascular morbidity [38]. Infants with 
severe BPD and pulmonary hypertension are at greater risk of mortality [39]. 
Systemic hypertension, arterial thickness and stiffness and increased systemic 
afterload may all contribute to BPD pathophysiology by altering left ventricular (LV) 
function and increasing pulmonary venous congestion by lowering end-diastolic 
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compliance [40].  A systematic review demonstrated that risk factors for the 
development of pulmonary hypertension in BPD infants were the duration of 
mechanical ventilation, length of stay, oligohydramnios, use of high frequency 
oscillation, small for gestational age, sepsis and severity of BPD.  Birth weight and 
gestational age were inversely related to pulmonary hypertension development [41].  
 
3.1 Inhaled nitric oxide 
Inhaled nitric oxide was shown in a non-randomised study to improve oxygenation in 
infants with BPD, but only 11 of 16 infants (gestational age 23-29 weeks) responded 
to 20 ppm of iNO, that is a 15% reduction in the inspired oxygen concentration (FiO2) 
[42]. Pulmonary hypertension in children with BPD has been shown to be responsive 
to changes in oxygen tension [43] and the combined treatment of supplemental 
oxygen and inhaled nitric oxide reduces pulmonary arterial pressures to almost within 
the normal range [43].  The most recent Cochrane review of three trials of late 
treatment of iNO did not show a significant reduction in mortality or BPD (RR 0.92, 
0.85-1.01) [44]. Consensus recommendations for the care of infants and children with 
pulmonary hypertension and BPD have been developed by the Pediatric Pulmonary 
Hypertension Network [45]. The report recommends that inhaled nitric oxide should 
be used for acute pulmonary hypertensive crises and weaned after a period of 
stabilisation. 
 
3.2 Sildenafil  
Sildenafil is a pulmonary vasodilator and, in infants with BPD associated pulmonary 
hypertension (BPD-PH), sildenafil can reduce pulmonary vascular resistance [46]. 
Sildenafil can also reduce pulmonary artery vaso-reactivity and prevent pulmonary 
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vessel remodelling [47]. In a case series of three extremely low birth weight (ELBW) 
infants with severe BPD, after four weeks of sildenafil treatment N-terminal pro b-
type natriuretic peptide (NTproBNP) levels decreased significantly, but only in one 
infant was there improvement in echocardiographic findings and respiratory scores 
[46]. A larger case series included twenty-three infants with BPD and pulmonary 
arterial hypertension [48]. Significant improvement in pulmonary arterial 
hypertension as assessed by ECHO was seen in 71% of infants, but only 35% of 
infants showed a significant clinical response to sildenafil treatment [48]. 
Retrospective data collection of twenty-two prematurely born infants with BPD-
associated pulmonary arterial hypertension who were treated with sildenafil was 
performed [49]. Infants were commenced on treatment with sildenafil at a median 
postnatal age of 49 weeks. Sildenafil use improved the ECHO markers of pulmonary 
arterial hypertension [49]. Four weeks after commencement of sildenafil, the infants 
had experienced a significant decrease in the FiO2 (0.57 to 0.42) with no change in the 
mean pCO2 levels. Sildenafil was well tolerated and both clinical and imaging 
improvements were seen [49]. Larger prospective studies are needed to assess 
whether sildenafil improves the long-term outcome in infants with severe BPD and 
pulmonary arterial hypertension.  Other pulmonary vasodilators are available, but  
have not been evaluated in infants with BPD beyond often single case reports.  
 
4. Anti-hypertensives 
The incidence of systemic hypertension has been variously reported to be between 7 
and 43% [38]. Infants have increased aorta wall thickness and stiffness [50], 
hypertrophy of the heart and reduced cardiac function [51]. 
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4.1 Captopril 
Captopril, an angiotensin-converting enzyme (ACE) inhibitor, has been used in 
neonates with hypertension and is thought to improve endothelial function and nitric 
oxide release [38].  It, has, however, only been reported to be evaluated in  a case 
series of six infants with severe BPD unresponsive to sildenafil and diuretics, five 
weeks after commencing treatment with captopril there was a significant reduction in 
the mean fraction of inspired oxygen (FiO2) (0.55 versus 0.29, p=0.03) and 
ventilatory requirements with a reduction in aorta intima media thickness [38]. 
Further studies are warranted to optimise management of this important complication.  
 
5.  Surfactant 
The trial of late surfactant (TOLSURF) was a randomized trial which enrolled those 
infants less than 28+7 days of gestational age who continued to require mechanical 
ventilation between seven to fourteen days after birth. All infants received inhaled 
nitric oxide with either surfactant or a placebo every one to three days up to a 
maximum of five doses. No significant effect of late surfactant use was demonstrated 
with regard to survival without BPD development [52].   At one year of age the 
infants who received late surfactant, however, required fewer hospital admissions for 
respiratory problems post discharge (p=0.03) [53]. Whether late surfactant improves 
longer term outcomes needs further study, not least given the surfactant abnormalities 
that have been reported in infants with evolving BPD.  
 
6.   Diuretics and fluid restriction 
Lung injury and arrested pulmonary and alveolar lung growth in infants with BPD can 
result in fluid overload, lung oedema and ineffective diuresis [54]. This occurs 
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because of increased permeability of pulmonary capillaries, which in turn increases 
airway resistance and reduces lung compliance [55]. Infants with BPD often tolerate 
fluid loads poorly and fluid restriction is a common practice. Yet, there is no evidence 
from RCTs to support such management.  Indeed, the only RCT to compare two fluid 
regimens in infants with BPD (145 ml/kg/day concentrated formula versus 180 
ml/kg/day) did not show any significant difference in the duration of supplementary 
oxygen or mechanical ventilation, weight loss or length of stay [56]. Nevertheless, 
diuretics were shown to be the seventh most frequently prescribed medication on the 
NICU in a comprehensive literature review [57].  In one study, more than 37% of 
infant born at less than 32 weeks of gestational age and weighing less than 1500 gms 
were exposed to diuretics [57]. A systematic review of studies of administration of 
frusemide, a loop diuretic, however, found limited data and inconclusive results 
regarding efficacy in infants with a developing chronic lung disease. It was concluded 
that a single dose of 1mg/kg of intravenous furosemide to such infants had a transient 
increase in oxygenation and lung compliance, but had no detectable or consistent 
positive effects when given earlier than three weeks of age [58]. A systematic review 
of six small trials assessed treatment of frusemide in preterm infants less than three 
weeks of age developing BPD had either inconsistent or no detectable effects [59].   
Treatment with frusemide has, however, been shown to be an independent risk factor 
for the development of nephrocalcinosis [60] and is associated with electrolyte 
disturbances, osteopaenia of prematurity and ototoxicity [57].  
 
Other diuretics used in infants with BPD are thiazides such as chlorothiazide which 
acts on the distal convoluted tubules.  They can cause hypokalaemia, hence they are 
often used in combination with potassium sparing diuretics such a spironolactone 
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[57].  A single study showed thiazide and spironolactone decreased the risk of death 
and tended to decrease the risk for remaining intubated after eight weeks of age in 
infants [59]. A systematic review of six studies of a four-week treatment with thiazide 
and spironolactone in preterm infants aged greater than three weeks with BPD 
showed only an improvement in lung compliance and reduced need for frusemide. In 
addition, the authors concluded the positive effects should be interpreted with caution 
as the numbers of patients included in the studies were small. Nevertheless, dual 
therapy of chlorothiazide and spironolactone is often given to infants with BPD [61]. 
Yet, spironolactone used with thiazide diuretics can cause hypercalciuria. 
 
Aerosolized diuretics can be used to specifically target pulmonary oedema, whilst 
avoiding adverse systemic side effects. A systematic review included eight studies of 
preterm infants less than three weeks of age with evolving or established BPD 
randomly allocated to receive an aerosolized loop diuretic. A single dose was found to 
transiently improve respiratory mechanics, however, there was no information 
available on the chronic administration effects and long-term outcomes [62]. It is 
important to develop a further evidence base for use of diuretics in infants with 
evolving or established BPD.  
 
7.   Immunisation 
Prematurely born infants with BPD are at a greater risk of respiratory viral infections 
in early childhood than term infants [63] and re-admission to hospital due to 
respiratory syncytial virus (RSV) [64]. Indeed, they are also at increased risk of 
reduced lung function [65] as are prematurely born infants who suffer rhinovirus 
infection [66]. The Palivizumab Consensus Group [67] recommended prophylactic 
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palivizumab to infants with BPD who were less than twelve months of age at the 
beginning of the RSV season. In addition, amongst infants between 12 and 24 months 
of age requiring medical management for BPD, such as supplemental oxygen, 
diuretics, corticosteroids or bronchodilators, in the six months before the RSV season 
then such infants should also be offered prophylactic therapy [67]. A prospective, 
cross-sectional study assessed 63 ex-preterm infants which included a control group 
who did not receive palivizumab and a matched group of infants who received 
palivizumab [68].  Fifty three percent of infants in the treatment group had a diagnosis 
of BPD. Within the first two years after birth, 27% of infants in the treatment group 
experienced wheeze compared to 70% of infants in the control group (p=0.001), but 
when assessed at school age, there was no significant difference between the two 
groups regarding lung function abnormalities or bronchodilator use [68].  Further 
evidence is required to determine whether immunisation in the second year will 
benefit BPD infants with regard to long-term outcomes.  
 
8.  Novel therapies 
8.1 Stem cell therapies 
In the prematurely born infant, neonatal lung arrested alveolar growth is associated 
with a decrease in the number of host mesenchymal stem cells (MSCs) [69]. MSCs, 
or multipotent stromal cells have immuno-modulatory properties and an ability to 
secrete trophic factors [70].  MSCs can be derived from adult bone marrow. Recent 
studies have shown promising results with MSCs obtained from the umbilical cord 
[71].  They are considered to be more primitive and superior in nature compared to 
adult derived MSCs [71], as they have low immunogenicity and anti-inflammatory 
and restorative properties [72]. Exogenous MSCs have been shown to act via both 
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direct and paracrine mechanisms to alter the biological properties of host MSCs via 
signalling of cells within the lung epithelium [72].  
 
Intratracheal umbilical cord blood derived MSCs administered to newborn rat pups in 
an experimental BPD model found treatment with MSCs restored lung structure and 
function where alveolar growth had previously been arrested [73]. Long term 
outcomes at six months of age showed that there were no adverse events in the stem 
cell group and there was a continued improvement in both lung structure and exercise 
capacity [73]. Those findings are consistent with neonatal mice exposed to hyperoxia 
treated with intravenous bone marrow derived MSCs who had normal numbers of 
alveoli on day fourteen of hyperoxia and reduced lung inflammatory markers [74].  A 
systematic review of 25 preclinical studies of assessment with MSCs demonstrated 
regardless of timing, dosage or route of administration, MSC administration was 
associated with significantly improved alveolarisation [75].  
 
There have been a few studies which have investigated the efficacy of MSCs in 
preterm infants with BPD. Six ex-prematurely born infants with established severe 
BPD were recruited into one study [76]. They had a median postnatal age of eight-
nine days. The infants were administered human amnion epithelial cells at a dosage of 
one million cells/kg intravenously. The first infant receiving treatment had a transient 
episode of cardiopulmonary instability during cell delivery with subsequent recovery.  
Subsequent ethical approval was gained to slow the infusion rate and include a cell 
filtration step prior to treating the remaining five infants. The results did not show any 
significant change to the infants’ respiratory support requirement following treatment 
[76]. The authors’ stated that the lack of significant effect in the infants, compared to 
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preclinical animal models might have been due to there being no dose escalation arm 
to the trial. A phase I clinical trial assessing the safety and feasibility of intratracheal 
human umbilical cord MSC in preterm infants used either 1x107 cells/kg in the first 
patient and the next six patients were given a higher dose (2x107 cell/kg) and 
delivered the cells between the 5th and 14th day after birth [77]. Nine preterm infants 
were recruited with a median birth weight of 793grams who had required continued 
ventilatory support after day five after birth. The median postnatal age of the infants 
when MSCs were administered was 10.4 days. The severity of BPD was lower in the 
MSC recipient group when compared to a matched untreated comparison cohort [77].  
At two year follow-up, none of the infants in the two treatment groups were 
discharged home on oxygen therapy, compared to 22% of the control infants [78]. In 
addition, in the treatment group, there were no long-term respiratory complications 
such as wheeze and asthma were observed and none of the infants were receiving 
continuous steroid or bronchodilator therapy [78].  It is important, however, to 
emphasize these results are not from a randomised trial.  
 
Due to the different harvesting and culture techniques of MSCs between laboratories 
it can be difficult to fully compare data from different clinical trials [79]. Robust 
quality controls and standardisation of techniques needs to be fully considered before 
approval of MSC derived therapies becomes routinely tested in neonates [79], not 
least despite early clinical trials showing some promising and positive results, there 
can be adverse outcomes due to the pro-inflammatory and myofibroblastic 
characteristics that MSCs possess [80]. MSCs exist in more than one different 
phenotype and can have the capability of promoting fibrosis and inflammation [81]. A 
meta-analysis of intravenous MSC treatment in adults and older children, however, 
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has not found any evidence of adverse events or malignancy up to sixty months 
following therapy [82]. In any subsequent study, robust follow up to assess long term 
outcomes needs to be included.  It has been suggested that a national registry of 
infants treated with this novel therapy should be established to ensure a standardised 
approach and allow adverse events and outcomes to be closely monitored.  
 
8.2 Erythropoietin 
 
Erythropoietin (EPO) has both anti-inflammatory and anti-oxidative properties [83] 
and EPO treatment during exposure to hyperoxia has been shown to improve alveolar 
structure and reduce fibrosis [84]. Administration of MSCs combined with EPO in a 
newborn mouse model in BPD resulted in a significant reduction in alveolar injury 
and degree of fibrosis compared with MSC therapy alone [83]. The mice treated with 
the combination therapy were shown to have smaller and more numerous alveoli [85]. 
These promising results need to be further explored.   
 
8.3 Deferoxamine 
 
The hypoxia-inducible factor (HIF)-1α is particularly important for the development 
of normal organs. HIF1α promotes angiogenesis by upregulating vascular endothelial 
growth factor (VEGF). The expression of HIF1α is immediately decreased in oxygen-
exposed preterm infants, leading to impaired alveolarization and angiogenesis.  
Deferoxamine is a bacterial siderophore and is most commonly used to chelate iron.  
In a mouse model aerosolised deferoxamine resulted in increased expression of 
HIF1α and activated downstream VEGF angiogenesis.  These promising results merit 
further study [86].   
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Expert commentary  
Bronchopulmonary dysplasia (BPD) is the most common long-term adverse outcome 
of very premature delivery and is associated with chronic respiratory morbidity. This 
includes chronic oxygen dependency which, in the most severely affected cases 
results in a supplementary oxygen requirement at home and affected children have 
troublesome respiratory symptoms requiring treatment and lung function 
abnormalities at follow up.  These problems may persist at least into young adulthood.  
Many studies have investigated possible preventative strategies, but it is equally 
important to identify optimum management strategies for infants with evolving or 
established BPD and the focus of this review.  Very few respiratory modalities have 
been robustly assessed in infants with evolving or established BPD and only short-
term outcomes have been considered. The worrying long-term effects of systemic 
corticosteroids, including neurological and respiratory problems needs further 
investigation and exploration of which infants are at greatest risk.  Whether the newer 
inhaled steroids will be efficacious in preventing long-term complications without 
adverse effects needs investigation.  Whether leukotriene receptor blockade may have 
any overall long-term advantages or be useful for individual infants merits study.  The 
incidence of pulmonary hypertension associated with BPD needs robustly assessing, 
as does the impact of inhaled nitric oxide in affected patients.  The role of sildenafil 
versus nitric oxide in hospitalised patients needs assessing as does its efficacy in 
infants discharged home on supplementary oxygen.  The evidence suggests diuretics 
are over-prescribed and have complications, evidence-based guidelines need to be 
produced. Further evidence is required to determine whether immunoprophylaxis 
against RSV in the second year will benefit BPD infants with regard to long-term 
outcomes.   The preliminary data on MSCs are interesting, but there needs to be much 
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more research to determine if such therapy should be investigated in RCTs with long-
term outcomes.  Equally, whether erythropoietin enhances the effects of MSCs needs 
further investigation.    
 
Five-year view 
Bronchopulmonary dysplasia is a common adverse, long term respiratory outcome of 
extremely premature birth. Regardless of whether BPD development occurs in the 
mild, moderate or severe form, many infants will face ongoing respiratory problems 
even into adulthood.  Stem cell treatment will in five years be likely established (or 
discredited) as the treatment of choice to prevent/treat BPD. During that time the 
safety of MSCs will have been established, but there will remain doubt as to the 
longer safety issues.  There is a growing interest in delivering quality improvement 
projects which will mean that evidence based practice will be increasingly adopted.  
This may result in reduction in, for example, the use of diuretics and corticosteroids.  
Given the increasing number of infants with BPD, hopefully appropriate RCTs of 
novel modes of ventilation will have established the optimum mode of respiratory 
support for that population.  In addition, effective, preventative strategies will have 
been identified, but given the multifactorial nature of BPD, there is unlikely to be a 
single magic bullet.  
 
Key issues 
• It should be noted that extremely prematurely born infants who did not 
develop BPD may also suffer such long-term adverse respiratory outcome.  As 
a consequence, it is important to assess the long-term efficacy of all treatments 
in extremely preterm infants regardless of the development of BPD.  
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• Effective, preventative strategies may reduce the proportion of infants 
developing BPD, hence it is important that multicentre, often international, 
studies are undertaken to ensure the sample size ensures robust results. 
• All RCTs must include long-term outcomes as many studies which have 
shown reductions in BPD or otherwise, have yielded different results at 
follow-up. 
• It is important to horizon scan to identify novel treatments.  
 
Recommendations 
In infants with evolving or established BPD who remain ventilator dependent: 
• Systematic corticosteroids should be considered in those who have made no 
progress over the first two weeks despite the absence of a PDA or infection 
and are requiring a high level of mechanical ventilatory support. 
• Diuretics should be considered in those who are not tolerating fluids and have 
poor growth. BPD infants who have received prolonged diuretics should be 
screened for nephrocalcinosis.  
• Bronchodilators should only be given to those infants who are wheezy and 
continued if they show a response ie a reduction in respiratory support. 
• BPD infants should be exubated as soon as possible. 
• BPD infants should be screened for systemic hypertension regardless of the 
use of corticosteroids. 
BPD infants should be screened for pulmonary hypertension 
Expert review in respiratory medicine  
25 
 
REFERENCES 
1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care. 
Med 2001;163:1723-1729. 
2. Steinhorn R, Davis JM, Gopel W et al. Chronic pulmonary insufficiency of 
prematurity: developing optimal endpoints for drug development. J Pediatr. 
2017;191:15-21. 
 * A review discussing appropriate end points for lung development other than 
BPD 
3. Greenough A. Long-term respiratory consequences of premature birth at less 
than 32 weeks of gestation. Early Hum Dev. 2013;89:S25-27. 
4. Greenough A. Long-term pulmonary outcome in the preterm infant. 
Neonatology. 2008;93:324-327. 
5. Guaman MC, Gien J, Baker CD, et al. Point Prevalence, Clinical 
characteristics, and treatment variation for infants with severe 
bronchopulmonary dysplasia. Am J Perinatol. 2015;32:960-967. 
6. Hunt KA, Dassios T, Ali K, et al. Prediction of bronchopulmonary dysplasia 
development. Arch Dis Child Fetal Neonatal Ed. 2018;103:F598-F599.  
7. Peng W, Zhu H, Shi H, et al. Volume-targeted ventilation is more suitable 
than pressure-limited ventilation for preterm infants: a systematic review and 
meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2014;99:F158-165. 
8. Hunt K, Dassios T, Ali K, et al. Volume targeting levels and work of 
breathing in infants with evolving or established bronchopulmonary dysplasia. 
Arch Dis Child Fetal Neonatal Ed. [Epub ahead of print 2018]. 
Expert review in respiratory medicine  
26 
 
9. Keszler M, Nassabeh-Montazami S, Abubakar K. Evolution of tidal volume 
requirement during the first 3 weeks of life in infants <800 g ventilated with 
volume guarantee. Arch Dis Child Fetal Neonatal Ed. 2009;94:F279-282.   
10. Schulze A. Respiratory mechanical unloading and proportional assist 
ventilation in infants. Acta Paediatr Suppl. 2002;91:19-22. 
11. Schulze A, Rieger-Fackedley E, Gerhardt T, et al. Randomised crossover 
comparison of proportional assist ventilation and patient triggered ventilation 
in extremely low birth weight infants with evolving chronic lung disease. 
Neonatology. 2007;92:1-7. 
12. Bhat P, Patel DS, Hannam S, et al. Crossover study of proportional assist 
versus assist control ventilation. Arch Dis Child Fetal Neonatal Ed. 
2015;100:F35-38  
13. Shetty S, Bhat P, Hickey A, et al. Proportional assist versus assist control 
ventilation in premature infants. Eur J Pediatr. 2016;175:57-61. 
14. Navalesi P, Longhini F. Neurally adjusted ventilatory assist. Curr Opin Crit 
Care. 2015;21:58-64. 
15. Jung YH, Kim HS, Lee J, et al.  neurally adjusted ventilatory assist in preterm 
infants with established or evolving bronchopulmonary dysplasia on high-
intensity mechanical ventilatory support: A single-center experience. Pediatr 
Crit Care Med. 2016;17:1142-1146. 
16. Shetty S, Hunt K, Peacock J, et al. Crossover study of assist control ventilation 
and neurally adjusted ventilatory assist. Eur J Pediatr. 2017;176:509-513. 
17. Lee J, Kim HS, Jung YH, et al. Neurally adjusted ventilatory assist for infants 
under prolonged ventilation. Pediatr Int. 2017;59:540-544. 
Expert review in respiratory medicine  
27 
 
18. DiBlasi RM, Crotwell DN, Poli J, et al. A pilot study to assess short-term 
physiologic outcomes of transitioning infants with severe bronchopulmonary 
dysplasia from ICU to two subacute ventilators. Can J Respir Ther. 2018;54. 
19. Shetty S, Hickey A, Rafferty GF, et al.  Work of breathing during CPAP and 
heated humidified high-flow nasal cannula. Arch Dis Child Fetal Neonatal Ed. 
2016;101:F404-407. 
20. Szczapa T, Gadzinowski J, Moczko J, et al. Heliox for mechanically ventilated 
newborns with bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal 
Ed. 2014;99:F128-F133.  
21.  Doyle LW, Cheong JL, Ehrenkranz RA, et al. Late (>7 days) systemic 
postnatal corticosteroids for prevention of bronchopulmonary dysplasia in 
preterm infants. Cochrane Database Syst Rev. 2017;10:CD001145.22.
 Lim G, Lee BS, Choi YS et al. Delayed dexamethasone therapy and 
neurodevelopmental outcomes in preterm infants with bronchopulmonary 
dysplasia. Pediatr Neonatol. 2015;56:261-267. 
23. Harris C, Crichton S, Zivanovic S, et al. Effect of dexamethasone exposure on 
the neonatal unit on the school age lung function of children born very 
prematurely. PLoS One. 2018;13:e0200243. 
* A study of 11 to 14  year olds demonstrating a dose effect of postnatal 
dexamethasone on impairment of lung function. 
24. Cheong JL, Burnett AC, Lee KJ, et al. Association between postnatal 
dexamethasone for treatment of bronchopulmonary dysplasia and brain 
volumes at adolescence in infants born very preterm. J Pediatr. 2014;164:737-
743. 
Expert review in respiratory medicine  
28 
 
25. Onland W, Offringa M, van Kaam A. Late (>7 days) inhalation corticosteroids 
to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database 
Syst Rev. 2017;8:CD002311.26. Slaughter JL, Stenger MR, Reagan PB, 
et al. Utilisation of inhaled corticosteroids for infants with bronchopulmonary 
dysplasia. PLoS One. 2014;9:e106838. 
27. Onland W, De Jaegera AP, Offringa M, et al. Systemic corticosteroid 
regimens for prevention of bronchopulmonary dysplasia in preterm infants. 
Cochrane Database Syst Rev. 2017;1:CD010941. 
28. Clouse BJ, Jadcherla SR, Slaughter JL. Systematic review of inhaled 
bronchodilator and corticosteroid therapies in infants with bronchopulmonary 
dysplasia: implications and future directions. PLoS One. 2016;11:e0148188. 
29. Kugelman A, Peniakov M, Zangen S, et al. Inhaled hydrofluoalkane-
beclomethasone dipropionate in bronchopulmonary dysplasia. A double-blind, 
randomised, controlled pilot study. J Perinatol. 2017;37:197-202. 
30. Shah SS, Ohlsson A, Halliday HL, et al. Inhaled versus systemic 
corticosteroids for preventing bronchopulmonary dysplasia in ventilated very 
low birth weight preterm neonates. Cochrane Database Syst Rev. 
2017;10:CD002058. 
31. Slaughter JL, Stenger MR, Reagan PB, et al. Inhaled bronchodilator use for 
infants with bronchopulmonary dysplasia. J Perinatol. 2015;35:61-66. 
32. Yuksel B, Greenough A. Ipratropium bromide for symptomatic preterm 
infants. Eur J Pediatr. 1991;150:854-857. 
33. Yuksel B, Greenough A, Maconochie I. Effective bronchodilator treatment by 
a simple spacer device for wheezy premature infants. Arch Dis Child. 
1990;65:782-785. 
Expert review in respiratory medicine  
29 
 
34. Ardhanareeswaran K, Mirotsou M. Lung stem and progenitor cells. 
Respiration. 2013;85:89-95. 
35. Peters-Golden M, Henderson WR, Jr. Leukotrienes. N Engl J Med. 
2007;357:1841-1854. 
36. Rupprecht T, Rupprecht C, Harms D, et al. Leukotriene receptor blockade as a 
life-saving treatment in severe bronchopulmonary dysplasia. Respiration. 
2014;88:285-290. 
37. Kim SB, Lee JH, Lee J, et al. The efficacy and safety of Montelukast sodium 
in the prevention of bronchopulmonary dysplasia. Korean J Pediatr. 
2015;58:347-353. 
38. Sehgal A, Krishnamurthy MB, Clark M, et al. ACE inhibition for severe 
bronchopulmonary dysplasia - an approach based on physiology. Physiol Rep. 
2018;6:e13821. 
39. Khemani E, McElhinney DB, Rhein L et al. Pulmonary artery hypertension in 
formerly premature infants with bronchopulmonary dysplasia: clinical features 
and outcomes in the surfactant era. Pediatrics. 2007;120:1260-1269. 
40. Stenmark KR, Abman SH. Lung vascular development: implications for the 
pathogenesis of bronchopulmonary dysplasia. Ann Rev Physiol. 2005;67:623-
661. 
41. Nagiub M, Kanaan U, Simon D, et al. Risk factors for development of 
pulmonary  hypertension in infants with bronchopulmonary dysplasia: 
systematic review and meta-analysis. Paediatr Respir Rev. 2017;23:27-32. 
42. Banks BA, Seri I, Ischiropoulos H, et al. Changes in oxygenation with inhaled 
nitric oxide in severe bronchopulmonary dysplasia. Pediatrics 1999;103:610-
618. 
Expert review in respiratory medicine  
30 
 
43. Mourani PM, Ivy DD, Gao D, et al. Pulmonary vascular effects of inhaled 
nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir 
Crit Care Med. 2004;170:1006-1013. 
44. Barrington KJ, Finer N, Pennaforte T. Inhaled nitric oxide for respiratory 
failure in preterm infants. Cochrane Database Syst Rev. 2017;1:CD000509. 
45. Krishnan U, Feinstein JA, Adatia I et al. Evaluation and management of 
pulmonary hypertension in children with bronchopulmonary dysplasia. J 
Pediatr. 2017;188:24-34. 
46. Qasim A, Dasgupta S, Aly AM, et al. Sildenafil use in the treatment of 
bronchopulmonary dysplasia-associated pulmonary hypertension: A case 
series. AJP Rep. 2018;8:e219-222. 
47. Baker CD, Abman SH, Mourani PM. Pulmonary hypertension in preterm 
infants with bronchopulmonary dysplasia. Pediatr Allergy Immunol Pulmonol. 
2014;27:8-16. 
48. Trottier-Boucher MN, Lapointe A, Malo J et al. Sildenafil for the treatment of 
pulmonary arterial hypertension in infants with bronchopulmonary dysplasia. 
Pediatr Cardiol. 2015;36:1255-1260. 
49. Tan K, Krishnamurthy MB, O'Heney JL, et al. Sildenafil therapy in 
bronchopulmonary dysplasia-associated pulmonary hypertension: a 
retrospective study of efficacy and safety. Eur J Pediatr. 2015;174:1109-1115. 
50. Sehgal A, Malikiwi A, Paul E, et al. Systemic arterial stiffness in infants with 
bronchopulmonary dysplasia: potential cause of systemic hypertension. J 
Perinatol. 2016;36:564-569. 
Expert review in respiratory medicine  
31 
 
51. Seghal A, Malikiwi A, Paul E, et al. A new look at bronchopulmonary 
dysplasia: postcapillary pathophysiology and cardiac dysfunction. Pulm Circ. 
2016;6:508-515. 
52. Ballard RA, Keller RL, Black DM et al. Randomized trial of late surfactant 
treatment in ventilated preterm infants receiving inhaled nitric oxide. J Pediatr. 
2016;168:23-29. 
53. Hascoet JM, Picaud JC, Ligi I et al. Late surfactant administration in very 
preterm neonates with prolonged respiratory distress and pulmonary outcome 
at 1 year of age: A randomized clinical trial. JAMA Pediatr. 2016;170:365-
372. 
54. Greenough A, Pahuja A. Updates on functional characterization of 
bronchopulmonary dysplasia - the contribution of lung function testing. Front 
Med (Lausanne). 2015;2:35. 
55. Fok TF. Adjunctive pharmacotherapy in neonates with respiratory failure. 
Semin Fetal Neonatal Med. 2009;14:49-55. 
56. Barrington KJ, Fortin-Pellerin E, Pennaforte T. Fluid restriction for treatment 
of preterm infants with chronic lung disease. Cochrane Database Syst Rev. 
2017;2:CD005389. 
57. Johnson AK, Lynch N, Newberry D, et al. Impact of diuretic therapy in the 
treatment of bronchopulmonary dysplasia and acute kidney injury in the 
neonatal population. Adv Neonatal Care. 2017;17:337-346. 
58. Stewart A, Brion LP. Intravenous or enteral loop diuretics for preterm infants 
with (or developing) chronic lung disease. Cochrane Database Syst Rev. 
2011;9:CD001453. 
Expert review in respiratory medicine  
32 
 
59. Stewart A, Brion LP, Ambrosio-Perez I. Diuretics acting on the distal renal 
tubule for preterm infants with (or developing) chronic lung disease. Cochrane 
Database Syst Rev. 2011;9:CD001817. 
60. Pacifici GM. Clinical pharmacology of the loop diuretics furosemide and 
bumetanide in neonates and infants. Paediatr Drugs. 2012;14:233-246. 
61. Stewart AL, Brion LP. Routine use of diuretics in very-low birth-weight 
infants in the absence of supporting evidence. J Perinatol. 2011;31:633-634.  
62. Brion LP, Primhak RA, Yong W. Aerosolized diuretics for preterm infants 
with (or developing) chronic lung disease. Cochrane Database Syst Rev. 
2006;3:CD001694. 
63. Garcia-Garcia ML, Gonzalez-Carrasco E, Quevedo S et al. Clinical and 
virological characteristics of early and moderate preterm infants readmitted 
with viral respiratory infections. Pediatr Infect Dis J. 2015;34:693-699. 
64. Paes B, Fauroux B, Figueras-Aloy J et al. Defining the risk and associated 
morbidity and mortality of severe respiratory syncytial virus infection among 
infants with chronic lung disease. Infect Dis Ther. 2016;5:453-471. 
65. Greenough A, Alexander J, Boit P, et al. School age outcome of 
hospitalisation with respiratory syncytial virus infection of prematurely born 
infants.  Thorax. 2009;64:490-495. 
66. Drysdale SB, Alcazar-Paris M, Wilson T, et al. Rhinovirus infection and 
healthcare utilisation in prematurely born infants.  Eur Respir J 2013;42:1029-
1036. 
67. Pignotti MS, Carmela Leo M, Pugi A et al. Consensus conference on the 
appropriateness of palivizumab prophylaxis in respiratory syncytial virus 
disease. Pediatr Pulmonol. 2016;51:1088-1096. 
Expert review in respiratory medicine  
33 
 
68. Prais D, Kaplan E, Klinger G et al. Short- and long-term pulmonary outcome 
of palivizumab in children born extremely prematurely. Chest. 2016;149:801-
808.  
69. van Haaften T, Byrne R, Bonnet S et al. Airway delivery of mesenchymal 
stem cells prevents arrested alveolar growth in neonatal lung injury in rats. 
Am J Respir Crit Care Med. 2009;180:1131-1142. 
70. Antunes MA, Laffey JG, Pelosi P, et al. Mesenchymal stem cell trials for 
pulmonary diseases. J Cell Biochem. 2014;115:1023-1032. 
71. Batsali AK, Kastrinaki MC, Papadaki HA, et al. Mesenchymal stem cells 
derived from Wharton's Jelly of the umbilical cord: biological properties and 
emerging clinical applications. Curr Stem Cell Res Ther. 2013;8:144-155.  
72. Simones AA, Beisang DJ, Panoskaltsis-Mortari A, et al. Mesenchymal stem 
cells in the pathogenesis and treatment of bronchopulmonary dysplasia: a 
clinical review. Pediatr Res. 2018;83:308-317. 
73. Pierro M, Ionescu L, Montemurro T et al. Short-term, long-term and paracrine 
effect of human umbilical cord-derived stem cells in lung injury prevention 
and repair in experimental bronchopulmonary dysplasia. Thorax. 
2013;68:475-484. 
74. Aslam M, Baveja R, Liang OD et al. Bone marrow stromal cells attenuate 
lung injury in a murine model of neonatal chronic lung disease. Am J Respir 
Crit Care Med. 2009;180:1122-1130. 
75. Augustine S, Avey MT, Harrison B et al. Mesenchymal stromal cell therapy in 
bronchopulmonary dysplasia: systematic review and meta-analysis of 
preclinical studies. Stem Cells Transl Med. 2017;6:2079-2093. 
Expert review in respiratory medicine  
34 
 
76. Lim R, Malhotra A, Tan J et al. First-in-human administration of allogeneic 
amnion cells in premature infants with bronchopulmonary dysplasia: a safety 
study. Stem Cells Transl Med. 2018;7:628-635. 
  
77. Chang YS, Ahn SY, Yoo HS et al. Mesenchymal stem cells for 
bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr. 
2014;164:966-972. 
 * A phase 1 dose escalation clinical trial in nine preterm infants suggesting 
administratioin of hUCB derived MSCs was safe and feasible. 
78. Ahn SY, Chang YS, Kim JH, et al.  Two-year follow-up outcomes of 
premature infants enrolled in the phase i trial of mesenchymal stem cells 
transplantation for bronchopulmonary dysplasia. J Pediatr. 2017;185:49-54.  
 * Follow up study of the above pilot study which showed compared to the 
comparison group, no significant difference in average hospitalisation rates, 
but as above the numbers included were small and the study was not 
randomised. 
79. Wuchter P, Bieback K, Schrezenmeier H et al. Standardization of Good 
Manufacturing Practice-compliant production of bone marrow-derived human 
mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy. 
2015;17:128-139. 
80. Waterman RS, Tomchuck SL, Henkle SL, et al. A new mesenchymal stem cell 
(MSC) paradigm: polarization into a pro-inflammatory MSC1 or an 
Immunosuppressive MSC2 phenotype. PLoS One. 2010;5:e10088. 
81. Gazdic M, Volarevic V, Arsenijevic N, et al. Mesenchymal stem cells: a 
friend or foe in immune-mediated diseases. Stem Cell Rev. 2015;11:280-287.  
Expert review in respiratory medicine  
35 
 
82. Lalu MM, McIntyre L, Pugliese C et al. Safety of cell therapy with 
mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis 
of clinical trials. PLoS One. 2012;7:e47559. 
83. Solling C. Organ-protective and immunomodulatory effects of erythropoietin-
-an update on recent clinical trials. Basic Clin Pharmacol Toxicol. 
2012;110:113-121. 
84. Luan Y, Zhang L, Chao S et al. Mesenchymal stem cells in combination with 
erythropoietin repair hyperoxia-induced alveoli dysplasia injury in neonatal 
mice via inhibition of TGF-beta1 signaling. Oncotarget. 2016;7:47082-47094.  
85. Zhang Z, Sun C, Wang J, et al.  Timing of erythropoietin modified 
mesenchymal stromal cell transplantation for the treatment of experimental 
bronchopulmonary dysplasia. J Cell Mol Med. 2018;22:5759-5763. 
86. Chen Y, Gao S, Yan Y, et al. Aerosolized deferoxamine administration in 
mouse model of bronchopulmonary dysplasia improve pulmonary 
development. Am J Transl Res. 2018;10:325-332. 
 * Interesting results from an animal model showing deferoxamine promoted 
pulmonary vascularisation and alveolarisation.  
 
 
 
